Protecting Clients Coast to Coast

If you suffered significant losses in Nidec stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nidec Corporation (“Nidec” or the “Company”) (OTC: NJDCY). STOCK DROP: On September 3, 2025, Nidec disclosed it had established a third-party committee to investigate suspicions of improper accounting. The Company further revealed its “investigations found multiple documents suggesting that . . . the Company and its group companies could have engaged in improper accounting with the involvement or knowledge of its or their management[.]” On this news, Nidec’s stock price fell $0.81, or 16.5%, to close at $4.11 per share on September 4, 2025, thereby injuring investors. Then, on September 26, 2025, Nidec disclosed further investigative findings of additional suspected inappropriate accounting practices, including “cases where the reported value for customs purposes was declared to be lower than the appropriate amount without legitimate reason.” The Company also revealed that it “received an audit report containing a disclaimer of opinion” from its auditor due to the “ongoing investigations by the third-party committee, other internal investigations, and other action[s].” On this news, Nidec’s stock price fell $0.29, or 6.6%, to close at $4.09 per share on September 26, 2025. Then, on October 23, 2025, Nidec published a press release announcing that it was withdrawing its year end forecast, and had decided not to pay a surplus dividend as “investigations by the Third Party Committee regarding suspected inappropriate accounting practices involving the Company and its group, as well as other internal investigations, are ongoing.” On this news, Nidec’s stock price fell $1.17, or 25.4%, to close at $3.43 on October 23, 2025. Finally, on October 27, 2025, the Tokyo Stock Exchange (“TSE”) designated Nidec under a Special Security alert in part because “TSE deems that the improvement of the internal management system of said listed company is highly necessary.” The alert noted that “[s]ince the initial issue was discovered, the scope of the investigation has continued to expand” and that “deficiencies have already been identified in the Company’s company-wide internal control systems (particularly in areas related to information and communication), as well as in the internal controls related to its accounting and financial closing processes.” On this news, Nidec’s stock price fell $0.80, or 20.3%, to close at $3.15 per share on October 27, 2025, thereby injuring investors further.  

Did You Lose Money in James Hardie Industries plc (NYSE:JHX) Stock? Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against James Hardie Industries plc (“James Hardie” or the “Company”) for alleged violations of federal securities laws. The firm reminds investors that they have until December 23, 2025 to seek appointment as lead plaintiff in the class action filed against the Company. The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that James Hardie Industries plc misled investors about the strength of its key North America Fiber Cement segment between May 20 and August 18, 2025. Despite knowing by April and early May that distributors were destocking inventory, the company falsely claimed demand remained strong and that stock levels were “normal.” Lead Plaintiff Deadline: December 23, 2025 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.

Did You Lose Money in Baxter International, Inc. (NYSE: BAX) Stock? Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International, Inc.  (“Baxter” or the “Company”) for alleged violations of federal securities laws. The firm reminds investors that they have until December 15, 2025 to seek appointment as lead plaintiff in the class action filed against the Company. The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (a) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (b) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (c) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (d) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (e) based on the foregoing, Baxter’s statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading. If you purchased BAX securities between February 23, 2022 and July 30, 2025 , you may be eligible to recover your losses. Lead Plaintiff Deadline: December 15, 2025 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.

If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD). STOCK DROP: On Monday, October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Preliminary data demonstrated patients’ baseline characteristics were similar across treatment arms, with the exception of percent predicted FVC, which was lower in the placebo-treated patients compared to the TTI-101-treated arms.